Loading news article.

FilingSEC EDGAR8-K

Prelude Therapeutics Receives FDA Clearance for Phase 1 Study of PRT13722

Sep 10, 2026, 07:29 ET · SEC accepted

StagePhase 1

Filing content

Prelude Therapeutics received FDA clearance for its IND application to initiate a Phase 1 study of PRT13722 in patients with HR+/HER2- breast cancer, with enrollment expected to begin in the fourth quarter of 2026.

AI summary of the filing. Please also check the source.

Related companies

Prelude Therapeutics IncPRLDView stock

Analyzed by WAPE AI.

Preparing English content…

Repost

Comments —

Loading comments…